The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels

BACKGROUND: The advent of Remicade® biosimilars, Remsima®, Inflectra® and, more recently, Flixabi®, has brought along the potential to decrease the costs associated with this therapy, therefore increasing its access to a larger group of patients. However, and in order to assure a soft transition, on...

Descripción completa

Detalles Bibliográficos
Autores principales: Magro, F., Rocha, C., Vieira, A. I., Sousa, H. T., Rosa, I., Lopes, S., Carvalho, J., Dias, C. C., Afonso, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153527/
https://www.ncbi.nlm.nih.gov/pubmed/30263065
http://dx.doi.org/10.1177/1756284818796956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153527/
https://www.ncbi.nlm.nih.gov/pubmed/30263065
http://dx.doi.org/10.1177/1756284818796956

Ejemplares similares